Skip to main content

The Challenges in Implementing Open Innovation in a Global Innovation-Driven Corporation

Buy Article:

$30.60 plus tax (Refund Policy)

Abstract:

OVERVIEW: Implementing open innovation approaches in a corporation that traditionally has relied on a closed innovation model will always be challenging. This paper describes our attempt to create an open innovation capability at Roche in both the pharmaceuticals and diagnostics divisions. In the journey, we have concluded that the navigation of two important hurdles drives any large company’s ability to embrace open innovation: creating the eureka moment that so vividly illustrates the value of open innovation activities that senior management no longer questions the need for them and shifting the company mindset to an open innovation culture.

Keywords: Innovation culture; Open innovation; Pharmaceutical/biotech

Document Type: Research Article

DOI: http://dx.doi.org/10.5437/08956308X5504079

Affiliations: 1: is the Head of New Innovation Models in Roche Partnering, where he explores alternatives to the conventional innovation models currently used in Roche. He has 23 years of experience in the pharmaceutical industry, including business development, chemistry, manufacturing and controls, and R&D strategy. He has a PhD in synthetic organometallic chemistry from the University of Wisconsin. 2: is a director of technology and innovation management working in the Roche Diagnostics Chief Technology Office. He has been with Roche for 13 years, engaged in technology strategy, assessment, and partnering activities. He is a member of the Roche global open innovation work team and is actively working to establish best practices for innovation management at Roche. Josh has a BS in biology from the University of California at Santa Barbara and an MBA from St. Mary’s College. 3: has 30 years of experience in technology management and currently works at Roche Diagnostics as senior director of technology management and Head of the U.S. Chief Technology Office. In this capacity, he oversees the identification and evaluation of emerging technologies relevant to the future of clinical diagnostics and is responsible for global open innovation initiatives within Roche Diagnostics. Terry received a Masters degree in pathology from the University of Western Australia.

Publication date: July 1, 2012

More about this publication?
iri/rtm/2012/00000055/00000004/art00006
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more